Box-plot graphs show the numerical distribution of CD68+pSTAT1+, CD68+pSTAT1-, CD68+CMAF+ and CD68+CMAF- cells/mm2 according to EBV-status (A) and Th-response group (B).

<p>The numerical distribution of CD163+pSTAT1+, CD163+pSTAT1-, CD163+CMAF+ and CD163+CMAF- cells/mm2 according to EBV-status and Th-response group is shown in C and D, respectively.</p

Kaplan-Meier curves in pediatric classical Hodgkin lymphoma, according to number of M1- or M2-like macrophages.

<p>A) Overall survival (OS) according to the numbers of CD68+CMAF+ macrophages. B) OS according to the numbers of CD163+pSTAT1+ macrophages. C) Progression-free survival (PFS) according to the numbers of CD163+CMAF+ macrophages. D) PFS according to the numbers of CD163+pSTAT1+ macrophages.</p

Clinical and histological variables according to M1/M2-like macrophage ratio.

<p>^a) In 2 cases, the numbers of CD68+pSTAT1+ and CD68+CMAF+ macrophages were similar.</p><p>^b) In 3 cases, the numbers of CD163+pSTAT1+ and CD163+CMAF+ macrophages were similar.</p><p>Clinical and histological variables according to M1/M2-like macrophage ratio.</p

Pie charts showing the kind of macrophage polarization in pediatric classical Hodgkin lymphoma, considering CD68 (A) or CD163 (C) as macrophage markers.

<p>Box-plot graphs show the numerical distribution of CD68+pSTAT1+, CD68+pSTAT1-, CD68+CMAF+ and CD68+CMAF- cells/mm2 (B), as well as CD163+pSTAT1+, CD163+pSTAT1-, CD163+CMAF+ and CD163+CMAF- cells/mm2 (D).</p

Examples of immunostains used to identify M1-like and M2-like macrophages in classical Hodgkin lymphoma.

<p>Expression of CD68 or CD163 is indicated by blue cytoplasmic/membranous staining. The expression of transcription factors pSTAT1 and CMAF is indicated by brown nuclear staining. Examples of cases with high numbers of M2-like macrophages are shown in A, (CD68+CMAF+ macrophages) and in C, (CD163+CMAF+ macrophages). Examples of cases with large numbers of M1-like macrophages are shown in B, (CD68+pSTAT1+ macrophages) and in D (CD163+pSTAT1+ macrophages) (original magnification: 400x). The sections were not counterstained.</p

Description of macrophage subpopulations in the tumor microenvironment of pediatric classical Hodgkin lymphoma and their association with progression free survival and overall survival.

<p>PFS: progression free survival. OS: overall survival.</p><p>Description of macrophage subpopulations in the tumor microenvironment of pediatric classical Hodgkin lymphoma and their association with progression free survival and overall survival.</p

Relationship of Epstein-Barr Virus and Interleukin 10 Promoter Polymorphisms with the Risk and Clinical Outcome of Childhood Burkitt Lymphoma

<div><p>Epstein-Barr virus (EBV) is an important environmental factor associated to the development of Burkitt lymphoma (BL) in endemic and intermediate risk regions. However, little is known about the contribution of genetic constitution to the development and clinical response of the disease. The aim of this work was to investigate the role of EBV and Interleukin 10 (<em>IL10</em>) single nucleotide polymorphisms (−1082A/G, −819C/T, −592C/A) and microsatellites (IL10.R and IL10.G) in susceptibility and clinical outcome in pediatric BL patients, in a region with intermediate EBV association frequency. The frequencies of <em>IL10</em> promoter Single nucleotide polymorphisms −1082A/G, −819C/T, −592C/A, and IL10.R and IL10.G microsatellites were compared in 62 pediatric patients and 216 healthy donors. <em>IL10</em> −1082GG and GCC/GCC genotypes were more frequent in patients than in controls, and associated to a higher risk of BL development (GG genotype OR 2.62, 95% CI, 1.25–5.51; <em>P</em> = 0.008; <em>Pc</em> = 0.024). EBV was detected in tumor samples by EBER-ISH in 54.1% of cases. EBV+ patients exhibited a better event free survival (EFS) (<em>P</em> = 0.019) than EBV− patients. Carriers of <em>IL10</em> R3-GCC had worse EFS (<em>P</em> = 0.028). Our results suggest a risk effect and an independent prognostic value of <em>IL10</em> polymorphisms and EBV in childhood BL patients.</p> </div

Case-control comparisons of genotypic and allelic frequencies of SNPs −1082 e −592 and genetic models of disease risk.

1<p>Numbers represent the number of individuals carrying each IL10 proximal genotype;</p>2<p><i>P</i> values column: for genotype comparisons, the first p value (italics) represents the comparison of BL cases vs. controls, by Chi square test; and the following represent the significance of the odds ratio (OR), as calculated by logistic regression, having case vs. control as dependent variable and each IL10 genotype as a covariate.</p

Distributions of Event free survival (EFS) probabilities according to (A) EBV status; (B) presence of IL10.01 family; (C) presence of IL10.G12 microsatellite allele at RG3; ■ positive; • negative; (D) IL10/EBV combination of risks; ▲EBV−/IL10.01−; ✱EBV+/IL10.01+; EBV−/IL10.01+; ♦ EBV+/IL10.01−.

<p>Distributions of Event free survival (EFS) probabilities according to (A) EBV status; (B) presence of IL10.01 family; (C) presence of IL10.G12 microsatellite allele at RG3; ■ positive; • negative; (D) IL10/EBV combination of risks; ▲EBV−/IL10.01−; ✱EBV+/IL10.01+; EBV−/IL10.01+; ♦ EBV+/IL10.01−.</p

Genotypic frequencies of SNP-1082G/A in EBV+ and EBV− Burkitt lymphoma cases.

<p>Genotypic frequencies of SNP-1082G/A in EBV+ and EBV− Burkitt lymphoma cases.</p